Aytu BioPharma (Aytu BioPharma) Change In Receivables : $4.19 Mil (TTM As of Mar. 2024)

View and export this data going back to 2008. Start your Free Trial

What is Aytu BioPharma Change In Receivables?

Aytu BioPharma's change in receivables for the quarter that ended in Mar. 2024 was $-0.52 Mil. It means Aytu BioPharma's Accounts Receivable increased by $0.52 Mil from Dec. 2023 to Mar. 2024 .

Aytu BioPharma's change in receivables for the fiscal year that ended in Jun. 2023 was $-7.15 Mil. It means Aytu BioPharma's Accounts Receivable increased by $7.15 Mil from Jun. 2022 to Jun. 2023 .

Aytu BioPharma's Accounts Receivable for the quarter that ended in Mar. 2024 was $29.93 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Aytu BioPharma's Days Sales Outstanding for the three months ended in Mar. 2024 was 151.76.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Aytu BioPharma's liquidation value for the three months ended in Mar. 2024 was $-49.29 Mil.

Aytu BioPharma Change In Receivables Historical Data

The historical data trend for Aytu BioPharma's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aytu BioPharma Change In Receivables Chart

Aytu BioPharma Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Change In Receivables

Get a 7-Day Free Trial

-1.16

-3.56

1.54

6.53

-7.15

Aytu BioPharma Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Change In Receivables	Get a 7-Day Free Trial															-8.50	5.18	-0.95	0.48	-0.52

Aytu BioPharma Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $4.19 Mil.

Aytu BioPharma (NAS:AYTU) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Aytu BioPharma's Days Sales Outstanding for the quarter that ended in Mar. 2024 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	29.925	/	17.993	*	91
=	151.76

2. In Ben Graham's calculation of liquidation value, Aytu BioPharma's accounts receivable are only considered to be worth 75% of book value:

Aytu BioPharma's liquidation value for the quarter that ended in Mar. 2024 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	19.76	-	98.086	+	0.75 * 29.925	+	0.5 * 13.193
=	-49.29

Aytu BioPharma Change In Receivables Related Terms

Thank you for viewing the detailed overview of Aytu BioPharma's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Aytu BioPharma (Aytu BioPharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Aytu BioPharma Inc (NAS:AYTU) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

AY20:Germany

Address

7900 East Union Avenue, Suite 920, Denver, CO, USA, 80237

Website

https://www.aytubio.com

Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complimentary therapeutic development pipeline including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. AR101/enzastaurin has received Orphan Drug designation from the FDA. The company operates in two segments Rx Segment, consisting of prescription pharmaceutical products and Consumer Health segments of which it generates maximum revenue from the Rx segment.

Executives

Christopher Brooke	officer: Chief Operating Officer	C/O AYTU BIOPHARMA, INC., 373 INVERNESS PARKWAY, SUITE 206, ENGLEWOOD CO 80112
Jarrett Disbrow	officer: Chief Business Officer	373 INVERNESS PARKWAY, SUITE 200, ENGLEWOOD CO 80112
John Jr. Donofrio	director	C/O AYTU BIOSCIENCE, INC., 373 INVERNESS PARKWAY, SUITE 200, ENGLEWOOD CO 80112
Carl Dockery	director	P.O. BOX 2477, LAKELAND FL 33806-2477
Vivian H Liu	director
Mark K Oki	officer: Chief Financial Officer	C/O ALEXZA PHARMACEUTICALS INC, 2091 STIERLIN COURT, MOUNTAIN VIEW CA 94043
Joshua R. Disbrow	director, officer: Chief Executive Officer	AMPIO PHARMACEUTICALS, INC., 5445 DTC PARKWAY, SUITE 925, GREENWOOD VILLAGE CO 80111
Abhinav Jain	director	C/O AYTU BIOPHARMA, INC., 373 INVERNESS PARKWAY, SUITE 206, ENGLEWOOD CO 80112
Wilmot B. Harkey	10 percent owner	C/O NANTAHALA CAPITAL MANAGEMENT, LLC, 130 MAIN ST. 2ND FLOOR, NEW CANAAN CT 06840
Daniel Mack	10 percent owner	C/O NANTAHALA CAPITAL MANAGEMENT, LLC, 130 MAIN ST. 2ND FLOOR, NEW CANAAN CT 06840
Nantahala Capital Management, Llc	10 percent owner	130 MAIN ST., 2ND FLOOR, NEW CANAAN CT 06840
Greg Pyszczymuka	officer: Chief Commerical Officer	C/O AYTU BIOPHARMA, INC., 373 INVERNESS PARKWAY, SUITE 206, ENGLEWOOD CO 80112
Richard I Eisenstadt	officer: Chief Financial Officer	4819 EMPEROR BOULEVARD, SUITE 400, DURHAM NC 27703
Gerald W. Mclaughlin	director	227 WASHINGTON STREET, SUITE 200, CONSHOHOCKEN PA 19428
Beth Hecht	director	C/O NEOS THERAPEUTICS, INC., 2940 N. HIGHWAY 360, GRAND PRAIRIE TX 75050